Clearing the BPH Path

Minimally Invasive Solution for BPH

Legal disclaimerIMPORTANT NOTICE

This presentation has been prepared by ProArc Medical Ltd. (the “Company”) solely for informational purposes. The information contained herein has been prepared to assist prospective investors in making their own evaluation of the Company and does not purport to be complete or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the Company and the data set forth in this information. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. The Company makes no representation or warranty as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any errors omissions in, this presentation. This presentation includes certain statements and estimates provided by the Company with respect to the projected future performance of the Company. Such statements, estimates and projections reflect various assumptions by management concerning possible anticipated results, which assumptions may or may not be correct. No representations are made as to the accuracy of such statements, estimates or projections. This presentation may contain statements that are not historical facts, referred to as “forward looking statements.” The Company’s actual future results may differ materially from those suggested by such statements. No assurance can be given that future events will occur or that projections will be achieved. Past performance is not a reliable indication of future performance. This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of the Company’s securities, or an offer to sell, or a solicitation of an offer to buy, the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. Prospective investors should not construe the contents of this presentation as business, legal, tax, investment or other advice. Each prospective investor should make his, her or its own inquiries and consult his, her or its own advisors as to the appropriateness and desirability of an investment in the Company and as to business, legal, tax and related matters concerning an investment in the Company.

An investment in the Company shall be allowed only to such number and category of investors in accordance with applicable laws and regulations and pursuant to a predetermined process. Accordingly, detailed information in connection with the investment shall be revealed and delivered only to a limited number of qualifying investors as provided by law.

Company Highlights

Team with

Track Record

Pre-Regulatory

Stage

Now Funding… Patents

granted/allowed

Scientific Publications

BPH Prostatetic Implant

CAGR 35%

Simple, Cost-Effective,

office procedure

2

Enlarged Prostate (BPH) Symptoms

• Frequency of urination

• Urgency

• Feeling of incomplete

emptying

• Weak stream

• Nocturia

• Sexual dysfunction

Normal Prostate

Bladder

Open Urethra

Source: The Canadian Journal of Urology, International Supplement, October 2015

Enlarged Prostate

Bladder

Obstructed Urethra

Benign Prostatic Hyperplasia (enlarged prostate)

affects ~50% of men 50+ and 90% of men 80+

3

Growing Costs

12 million men are

actively treated in

the US each year

Prevalence of BPH

is increasing with

aging population

$4 billion annually in direct

treatment costs in the US2

Source: (1) (2) The Canadian Journal of Urology, International Supplement, October 2015

Diagnosis and

treatment of BPH

represents the

largest segment of

urologic practice,

representing 23% of all office visits.1

4

MedicationEffective in relieving

symptoms but expensive with

diminishing effect over time

SurgeryExpensive with steep

learning curve

Current Treatments Are Not Cost Effective

Dizziness, fainting,

fatigue, headache, nasal

congestion, retrograde

ejaculation and more

Pain, bleeding,

impotence,

incontinence, urethral

stricture (narrowing)

The market seeks

a simple,

cost-effective,

minimally invasive

BPH treatment

Do NothingSome patients accept their

condition and are reluctant to

undergo treatment

Risk of severe kidney

damage, acute urinary

retention, urinary

bleeding and more

Side Effects

5

Fastest Growth: Sub-Surface Implants

Sub-Surface Prostatic

Urethral Lift Implant

35% CAGR

6

TURP (mono or bipolar)

Thermal Ablation

Laser Surgery

Steam (Rezum)

Aquablation

Prostatic Artery Embolization

Sub-Surface Prostatic Urethral Lift Implant

Transurethral Resection/Ablation of the Prostate

Sub-surface prostatic urethral lift Implant

Sexual function preservation

Minor side effects

Reversible

Long procedure time 30-45 min

Irreversible

High probability of sexual dysfunction

Prostatic Urethral Lift

Our Solution: ClearRingTM

• Patented technology

• Office-based

• Easy to learn

• Fast & simple procedure

• Reversible procedure

ProArc Medical Animation Link

The ClearRingTM

implant is

positioned inside

the prostate just

under the surface

and reshapes the

prostatic urethra.

It provides 360º

support along the

urethra.

Sub-Surface Prostate Implant

7

Scientific Publication in the EUROPEAN UROLOGY FOCUS

8

Clinical Evidence

AfterBefore

9

ClearRing Advantages

ClearRing has the

potential to be the

most financial

attractive solution

for urologists

ClearRing

• Safe: fully implantable inside the prostate;

• Economic incentive: With comparable effectiveness, ClearRing offers an

attractive financial incentive with a single Clearing Implant

• Simple: shorter procedure time; expected shorter learning curve;

expected use by more urologists

• ClearRing offers a 100% reversible treatment

10

Executive Team & Scientific Advisors

David Nitsan, CEOIsrael

Yair Feld, MDFounder, Medical Director,

Israel

Gilad Heftman, R&D

Israel

Frank Mastandrea, MDFL, United States

Fernando Gomez Sancha, MD

Spain

Egils Vjiaters, MDLatvia

11

Thank You

david@proarcmedical.com